Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ruxolitinib in Pancreatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas.~* Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2~* Received 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy).~* ≥ 2 weeks elapsed from the completion of previous treatment regimen and participants must have recovered or be at a new stable baseline from any related toxicities.~* Radiographically measurable or evaluable disease~* An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:~  * Criteria:~    1. mGPS of 1: C-reactive protein (CRP) \> 10 mg/L and albumin ≥ 35 g/L~   2. mGPS of 2: CRP \> 10 mg/L and albumin \< 35 g/L~Exclusion Criteria:~* Received more than 1 prior regimen for advanced or metastatic disease.~* Ongoing radiation therapy, radiation therapy administered within 30 days of enrollment~* Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).~* Current or previous other malignancy within 2 years of study entry without sponsor approval~* Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), ruxolitinib, or any of their excipients.~* Prior treatment with a JAK inhibitor for any indication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib plus capecitabine (Type: EXPERIMENTAL): None
- Placebo plus capecitabine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).